Your buyer in Boston, Munich, or Manchester evaluates your device in 90 seconds. Right now your website is built for the buyer in Seoul.

A clinical specialist at a US teaching hospital is evaluating endoscopes for a procurement cycle. She has a shortlist of seven manufacturers, three of which are Korean, two Japanese, one Taiwanese, and one German. She opens the first Korean manufacturer's website. The homepage is in Korean with an English flag toggle in the corner. She clicks it. The English version loads with one product line surfaced, a stock image of the headquarters, and a contact form with no regional routing. The 510(k) clearance number she needs to verify with the FDA is nowhere on the product page. She checks the source code for structured data. There is none. Sixty seconds in, she closes the tab and opens the next manufacturer.

That manufacturer just lost a £400,000 procurement deal in ninety seconds. Not on the device, which has a strong 510(k) clearance and competitive specifications. On the website. The product was excellent; the artefact representing the product was not built for her.

This pattern plays out tens of thousands of times per quarter across US, EU, and UK procurement cycles. The Asian medical device manufacturer ships a clinically and commercially strong product into a Western digital experience that was built for the home market. The gap is the most expensive line item nobody on the team measures.

Three structural reasons.

First, the Western buyer journey starts before the contact form. A Korean or Japanese buyer typically reaches a manufacturer through trade-show contact, distributor referral, or KOL recommendation. The website is a confirmation artefact. A US biomedical engineer or EU procurement officer reaches the manufacturer through Google search, ChatGPT recommendation, or peer-reviewed citation in a clinical paper. The website is the discovery and evaluation artefact. Two different jobs, one site.

Second, regulatory transparency is a primary trust signal in Western procurement, not an "About" page link. The US Food and Drug Administration 510(k) database, the EU EUDAMED registry, the UK MHRA registration register: all of these are public databases the buyer cross-references against your site within their first three minutes. Your site needs to make that cross-reference frictionless: clearance number visible, notified body identified, certificate number and validity date surfaced. Most Asian-manufacturer sites omit these or hide them in a corporate brochure PDF.

Third, clinical evidence is the buyer's second filter. Hospital procurement and clinical specialists weight peer-reviewed publications, comparative effectiveness studies, and outcomes data more than marketing copy. Your published research belongs adjacent to the product page that uses it, not in a separate "News" section. Most home-market sites bury clinical evidence in PDF newsletters or skip it entirely on the assumption that the distributor relationship carries it.

1. Regulatory clarity in the first 60 seconds

FDA 510(k) K-number, EU CE mark with notified body identifier (TÜV SÜD 0123, BSI 0086, DEKRA 0124, where applicable), MDR class, ISO 13485 certificate number with issuing body, MDSAP status. Surfaced on the product page itself, not behind a regulatory PDF download. A small badge with the K-number that links to the FDA 510(k) database is the single highest-leverage element on the page.

2. Clinical evidence linked per product

Peer-reviewed publications, comparative studies, outcomes data, and post-market surveillance reports linked from the product page. Each citation rendered as a structured reference (DOI, journal name, year, lead author affiliation) so AI engines can extract and cite it. Hospital procurement teams want to verify your clinical claims; researchers want to cite your data. Both are upstream of revenue.

3. English-primary regional sub-paths with proper hreflang

The /us/, /eu/, and /uk/ sub-paths each present native English content with region-specific regulatory positioning, distributor information, and clinical evidence relevant to that market's procurement standards. Bidirectional hreflang signals to Google and AI engines which page belongs to which market. The home-market language remains primary on the corporate root, with regional flows existing alongside, not as translations of the corporate page.

4. Distributor finder and distributor application

An interactive map showing your authorised distributors per region, with current contact details and product line coverage. A separate flow for prospective distributors to apply for territorial rights, with the qualification form mapped to your existing channel partner programme. Most Asian-manufacturer sites have a static list with broken phone numbers, or no distributor information at all.

5. Technical documentation as findable, structured documents

Instructions For Use (IFU), Directions For Use (DFU), service manuals, and technical specifications hosted as structured documents per product per language. EU MDR Article 41 mandates IFU availability in the official language of every member state where the device is sold. Hosting these as findable, linkable documents (rather than gated PDFs behind a contact form) is what serious manufacturers do. Notified bodies will check this during audit.

6. AI search and category-query visibility

When a US biomedical engineer asks ChatGPT, Perplexity, or Google AI Overviews "best Korean ENT endoscope manufacturer with FDA 510(k) clearance", you need to be in the citation list. The work that drives this is structured: MedicalDevice and Service schema, FAQPage schema on category pages, peer-reviewed citation density, clean entity graph (Wikidata Q-item, sameAs unification across LinkedIn / Crunchbase / industry directories), and a few well-placed thought-leadership pieces in trade publications.

A 12-to-18-week build. Three weeks of discovery and regulatory documentation gathering. Six to eight weeks of build covering the foundation, regional flows, and the regulatory clarity layer. Two weeks of distributor architecture (interactive map, application portal, partner-side dashboard). Three to four weeks of content production: clinical evidence library population, IFU and DFU document migration with native medical writer review per language, and the AI search content layer.

Stack is Astro for the public marketing layer (static, fast, SEO-grade), Supabase for the distributor portal and authenticated content, Cloudinary or imgix for the clinical and product image pipeline, and a translation workflow with native medical writers per target language. Schema rollout on every page: MedicalDevice or Product, Organization with sameAs to Crunchbase / LinkedIn / FDA establishment registration, Service per product line, FAQPage on category and FAQ pages, BreadcrumbList throughout. Performance: WCAG 2.1 AA accessibility (US procurement requirement), Core Web Vitals passing on mobile, sub-2-second LCP under 4G simulation.

The work is sequenced so the regulatory clarity layer ships first, the clinical evidence library second, and the AI search programme third. Each phase produces a measurable outcome: the regulatory layer reduces buyer friction in the first 60 seconds; the clinical library positions the brand for hospital procurement and KOL citation; the AI search programme captures the discovery flow that increasingly precedes the contact form.

Three shapes of project I turn down on the kickoff call.

The "translate the existing home-market site into English" brief. The structural mismatch is not a translation problem. A machine-translated or even human-translated home-market page is the wrong artefact for a Western buyer; the buyer journey is different, the trust signals are different, the regulatory positioning is different. The right brief is "build a Western-buyer-flow site that lives alongside the home-market site". I will turn down the translate-only version and explain why, then offer the right shape.

The "we have not received our first Western clearance yet" brief. If the manufacturer does not yet have a 510(k), CE mark, or UKCA mark for at least one product, the regulatory clarity layer (which is the highest-leverage element of the build) has nothing to surface. The right move is to wait until the first clearance is granted, then ship the site sized to that single product, then expand as further clearances arrive. Building a Western-flow site without a clearance to anchor it produces a marketing site, not a procurement-grade artefact.

The "we want to build this in three weeks for a trade show" brief. Trade-show microsites are a different shape and a separate engagement. The 12-to-18-week build is a procurement-grade artefact intended to support multi-million-pound deal cycles. Compressing it into three weeks produces a deck-quality output, not a procurement-grade output. I will build a trade-show microsite as a focused 4-week project alongside, but not instead of, the procurement-grade work.

Three forces converged this year and the next eighteen months are the highest-leverage window for this work.

EU MDR enforcement reached full effect in late 2025. Notified body audits in 2026 are checking IFU translation rigour, post-market surveillance evidence, and EUDAMED registration completeness. Manufacturers whose websites do not surface this material at procurement-grade fidelity are losing CE certificate renewals at higher rates than the industry expected. The website is now part of the audit surface, not just the marketing surface.

US hospital procurement digital transformation accelerated through 2024 and 2025. Group Purchasing Organisations (Vizient, Premier, HealthTrust) are running RFP intake through digital portals that pull manufacturer data from the public website. A site that does not surface FDA clearance information, clinical evidence, and technical specifications in a procurement-portal-friendly way (structured data, downloadable spec sheets per product, machine-readable regulatory information) loses GPO inclusion at a rate that did not exist three years ago.

AI-driven vendor discovery is reshaping the early stage of the buyer journey. ChatGPT, Perplexity, Google AI Overviews, and Bing Copilot are increasingly the first place a Western biomedical engineer or procurement officer asks "who manufactures X with Y clearance". The brands that ship AI-citation-ready content this year define the consideration set for the next eighteen months. The brands that wait until 2027 spend three years catching up to incumbents who already exist in the citation patterns.

Why does a Western-buyer flow need to be separate from the home market site?

Western buyers evaluate on different signals than Asian domestic buyers. Regulatory clearance numbers visible early, peer-reviewed clinical evidence linked per product, MDR-compliant IFU translations, and region-specific distributor or direct sales contact. A single home-language site cannot serve both audiences without one feeling like a translation artefact. The pattern that works is regional sub-paths (/us/, /eu/, /uk/) with native English copy and proper hreflang.

What regulatory information should the public site surface?

For US: 510(k) K-number, De Novo or PMA where applicable, FDA establishment registration number, product classification. For EU: CE marking with notified body number, MDR class, EUDAMED registration where required. Across both: ISO 13485 certificate number and issuing body, MDSAP status, downloadable Declaration of Conformity per product. Surface these on the product page itself, not in an "About" section.

Is machine translation acceptable for medical device websites?

No. EU MDR Article 41 requires IFU translations of clinical-grade quality in the official language of every member state where the device is sold. Machine translation of regulatory or clinical content fails MDR compliance review and can trigger CE certificate suspension. Native medical writers per target language for regulatory and clinical content; machine translation acceptable only for non-regulatory marketing copy.

How long does the build take?

Twelve to eighteen weeks for a typical mid-market manufacturer with three to six product lines. Three weeks discovery, six to eight weeks build, two weeks distributor architecture, three to four weeks content production. Faster timelines possible for single-product launches.

Why does AI search visibility matter for medical device manufacturers in 2026?

Western buyers increasingly start vendor discovery on ChatGPT, Perplexity, or Google AI Overviews. A US biomedical engineer asking "best Korean ENT endoscope manufacturer with FDA 510(k) clearance" receives an answer with three to five cited sources. If your brand is not in those citations, you are not in the consideration set, regardless of traditional SEO position. The work that drives AI citations is additive to traditional SEO and pays back inside 90 days for manufacturers with real clearance documentation to cite.

What does this cost?

Build £25,000 to £80,000 depending on product line count and regional scope. Retainer £4,000 to £8,000 per month for content, regulatory updates, AI search tracking, and distributor portal maintenance. First-year total typically £75,000 to £160,000, materially below the cost of a single missed FDA 510(k) submission cycle or a botched MDR re-certification.

The build, £25,000 to £80,000, 12 to 18 weeks

The lower end covers single-product-line manufacturers with US-only scope and existing English content. The upper end covers multi-product-line manufacturers with US plus EU plus UK scope, the full clinical evidence library, native medical writer translation pipeline for IFU and DFU documents, and distributor portal architecture. Most engagements land between £40,000 and £60,000. Project pricing is fixed-scope; surprises are absorbed inside the engagement, not billed as variations.

The retainer, £4,000 to £8,000 per month, ongoing

Content production (one to three pieces per month aligned to the AI search programme), regulatory information updates as new clearances arrive, AI citation tracking across ChatGPT / Perplexity / Gemini / Google AI Overviews, distributor portal maintenance, and quarterly executive review with Western-market analytics. Three-quarter minimum commitment because the AI search surfaces re-crawl on a four-to-eight-week cycle and shorter engagements do not let the data settle.

The free AI Citation Checker derives five buyer queries for your category and reports whether your brand is cited in the top 10 organic results that ChatGPT and Perplexity pull from, plus whether Google AI Overviews are running on those queries today. No login, no email, takes about 20 seconds. Useful as a starting line for the conversation.

Book a 30-minute call. Tell me your product lines, your existing Western clearances, and the three target markets that matter most for the next twelve months. By the end of the call you have a stack pick, a price range, a delivery window, and a clear sense of whether I am the right person for this engagement. No deck, no qualification screen.